aboutsummaryrefslogtreecommitdiff
path: root/gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_1
diff options
context:
space:
mode:
authorShelbySolomonDarnell2024-10-17 12:24:26 +0300
committerShelbySolomonDarnell2024-10-17 12:24:26 +0300
commit00cba4b9a1e88891f1f96a1199320092c1962343 (patch)
tree270fd06daa18b2fc5687ee72d912cad771354bb0 /gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_1
parente0b2b0e55049b89805f73f291df1e28fa05487fe (diff)
downloadgn-ai-master.tar.gz
Docker image built to run code, all evals run using R2RHEADmaster
Diffstat (limited to 'gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_1')
-rw-r--r--gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_165
1 files changed, 65 insertions, 0 deletions
diff --git a/gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_1 b/gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_1
new file mode 100644
index 0000000..886b472
--- /dev/null
+++ b/gnqa/paper2_eval/data/dataset/human/intermediate_files/human_de_gn_1
@@ -0,0 +1,65 @@
+{
+ "titles": [
+ "2021 - Human Molecular Genetics and Genomics.pdf",
+ "2015 - A new age in functional genomics using CRISPR Cas9 in arrayed library screening.pdf",
+ "2016 - Genome editing comes of age.pdf",
+ "2018 - Neuro-Immuno-Gene- and GenomeEditing-Therapy for Alzheimer\u2019s.pdf",
+ "2016 - Genome editing comes of age.pdf",
+ "2016 - Dissecting diabetes metabolic disease.pdf",
+ "2020 - Functional Genomics in Pancreatic \u03b2 Cells Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research.pdf",
+ "2021 - Human Molecular Genetics and Genomics.pdf",
+ "2018 - Neuro-Immuno-Gene- and GenomeEditing-Therapy for Alzheimer\u2019s.pdf",
+ "2020 - Clinical Genetics and Genomics of Aging.pdf"
+ ],
+ "extraction_id": [
+ "08a2c0e6-8ca8-5a72-974c-3f1e27ba1b15",
+ "49b81415-ef6f-5cc4-bb30-71e971070ebe",
+ "190e8838-4f61-5431-8848-98564ded7140",
+ "66dbf4f0-2b37-5219-9eeb-0a560df8d888",
+ "c7b143d7-347c-5160-bfd4-82283b342d7d",
+ "ebabc771-1777-56c1-9101-c1677c5ae908",
+ "fe5bf2df-2eda-5ef0-8aad-79bbc5b898d6",
+ "08a2c0e6-8ca8-5a72-974c-3f1e27ba1b15",
+ "3dd04f3c-0dc4-5bf7-aff6-3d9282761a2e",
+ "54972d7f-0ddc-5076-9d58-890a85f71332"
+ ],
+ "document_id": [
+ "68e362a5-e580-5a4d-8d41-6a138c873ede",
+ "20df9469-e1cc-500e-ac30-fbba981d7aee",
+ "4078087a-c2a4-5c58-95b5-4ae243794800",
+ "cc0a025b-71e7-5712-bbf7-4ee1e0f769ef",
+ "4078087a-c2a4-5c58-95b5-4ae243794800",
+ "eee2f79d-e093-52fb-871a-798fd859235e",
+ "51350055-d53c-5692-ab53-337b8a8bafd6",
+ "68e362a5-e580-5a4d-8d41-6a138c873ede",
+ "cc0a025b-71e7-5712-bbf7-4ee1e0f769ef",
+ "62b635c3-040e-512a-b016-6ef295308a1e"
+ ],
+ "id": [
+ "chatcmpl-ADZ9J7DmFDWNhxuisZ7zPEZmBG259",
+ "ffbca864-26db-5f36-8ad4-3b8d24d46de6",
+ "2fbabecd-22c1-5570-8f38-bc934d463710",
+ "6dfc48be-a762-55d6-9aba-799d80e8140d",
+ "a4aa9de7-cc9f-5c3f-a9fe-c37a47faa5b7",
+ "ff2d183b-c5be-5e05-94c8-e2db379dcd96",
+ "a3d6f231-29aa-5cf6-b856-004d3d9dd9c1",
+ "6ba3cf43-be4d-561f-ad84-f79921cab37e",
+ "4474c4e9-bc07-5610-8bb2-dafe5c95774b",
+ "77b11b36-35c8-55dc-a2d1-25d5e4ca218d",
+ "176b7aa5-17ef-590d-8807-1aa7def904bb"
+ ],
+ "contexts": [
+ "neered nucleases, CRISPR-Cas9 tools have accelerated the pace of genomic research by permitting highly efficient knockouts or edits of virtually any gene in cells or model organisms. Multiple CRISPR-Cas9based clinical trials are in progress or are expected to begin soon. Although Cas9- engineered cells havent yet dem - onstrated efficacy at scale, early trial results suggest that such cells are stable and dont cause acute adverse reactions in humans. Long-term safety is yet to be de -",
+ "stageissetforCRISPRtomakeanenormousimpactongenomic screening and thus scientic discovery in the coming years, and recent demonstrations of this system have shown great promise (Shalem etal., 2015 ).However,a number of technical challenges must be addressed in order to maximize the benet of this technology. In this review, we will discuss current applications of CRISPR in functional genomics and provide a perspective on futuredevelopmentsinthisarea. CRISPR/Cas9 Genome Editing",
+ "heralding the age of genome editing. Furthermore, Cas9 or guide RNAs have been linked to various effector proteins to enable targeted gene regulation 12,13 and epigenome modifications14,15. It is worth noting, however, that many of these feats had been demonstrated previously using other nucleases or DNA-binding proteins 1,16. In this Perspective, I shed light on early genome editing platforms that laid the groundwork for the widespread use of CRISPRCas9 in research and medicine (Fig. 1 ).",
+ "CRISPR/CAS9 HOLDS SIGNIFICANT PROMISE FOR THE DEVELOPMENT OFNEW AD MODELS AND PRECISIONTARGETED AD THERAPY Clustered regularly interspaced short palindromic repeat (CRISPR)-Cas nucleases have revolutionizedthe eld of gene editing and have tremendous appli-cation in the eld of molecular medicine [98102].Despite a signicant surge in CRISPR/Cas9-mediated genome editing in various disease models,the progress in the eld of AD has lagged behindsubstantially. We believe that genome editing can sig-",
+ "81. Applications for CRISPRCas9 beyond genome editing",
+ "cline- or Tet-regulated Cas9 system. Current CRISPR/Cas systems arefrom Streptococcus pyogenes ,Streptococcus thermophilus ,Neisseria meningitides and Treponema denticola .2.5. Caveats of advanced genome editing tools Off-target effects . The DNA-binding domains of ZFNs and TALENs need to be very speci c for the target site to avoid off-target cleavage, which results in unwanted mutations and potentially cytotoxic effects [27]. CRISPR/Cas9 is also known to generate off-target alterations,",
+ "on transcriptional interfere nce (CRISPRi) and activation (CRISPRa) have also harnessed Cas9-based technologies for use in genome-wide studies ( 59,174). In addition, recent improvements in lentiviral library generation and propagation,as well as large-scale DNA and RNA synthesis, have allowedCRISPR-Cas9 technology to be exploited across multiple modelplatforms ( 59,175178). nCas9 The CRISPR-Cas9 system can tolerate certain mismatches to the DNA target since the required gRNAs are short. A disadvantage,",
+ "CRISPR-Cas9 can be used to in - duce genome edits by creating targeted DNA breaks that trigger site-specific DNA repair. In next- generation formats, it can also control the transcriptional output of genes or alter genome se - quences using a process of nu - cleotide base editing that does not require repair of DNA breaks. As these technolo - gies continue to mature, it will become increasingly possible to alter cellular genomes efficiently and accurately. Coming on the heels of engi -",
+ "S.P . Raikwar et al. / Alzheimers Disease: New Therapeutic Horizons 333 gene editing efciency of the CRISPR/Cas9 systems.",
+ "13. Kleinstiver BP, etal. High-fidelity CRISPRCas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:4905. 14. Brane A, Tollefsbol T.Targeting telomeres and telomerase: studies in aging and disease uti- lizing CRISPR/Cas9 technology. Cells. 2019;8:186. 15. Wang H, etal. One-step generation of mice carrying mutations in multiple genes by CRISPR/ Cas-mediated genome engineering. Cell. 2013;153:9108."
+ ],
+ "answer": "### Potential Benefits of CRISPR-Cas9: 1. **Accelerated Genomic Research**: CRISPR-Cas9 tools have significantly accelerated the pace of genomic research by allowing highly efficient knockouts or edits of virtually any gene in cells or model organisms [1]. 2. **Clinical Trials and Stability**: Multiple CRISPR-Cas9-based clinical trials are in progress, and early trial results suggest that CRISPR-engineered cells are stable and do not cause acute adverse reactions in humans [1]. 3. **Functional Genomics**: CRISPR is set to make a significant impact on genomic screening and scientific discovery, with recent demonstrations showing great promise [2]. 4. **Targeted Gene Regulation and Epigenome Modifications**: CRISPR-Cas9 has been linked to various effector proteins to enable targeted gene regulation and epigenome modifications [3]. 5. **Precision Medicine**: CRISPR-Cas9 holds significant promise for the development of new disease models and precision-targeted therapies, particularly in molecular medicine [4]. 6. **Versatility in Applications**: CRISPR-Cas9 can induce genome edits by creating targeted DNA breaks that trigger site-specific DNA repair. It can also control the transcriptional output of genes or alter genome sequences using nucleotide base editing, which does not require DNA break repair [8]. ### Potential Risks of CRISPR-Cas9: 1. **Off-Target Effects**: CRISPR-Cas9 is known to generate off-target alterations, which can result in unwanted mutations and potentially cytotoxic effects [6]. 2. **Technical Challenges**: There are several technical challenges that need to be addressed to maximize the benefits of CRISPR technology [2]. 3. **Long-Term Safety**: While early trial results are promising, the long-term safety of CRISPR-engineered cells is yet to be determined [1]. 4. **Mismatch Tolerance**: The CRISPR-Cas9 system can tolerate certain mismatches to the DNA target, which could be a disadvantage as it may lead to unintended edits [7]. In summary, while CRISPR-Cas9 offers numerous benefits such as accelerating genomic research, enabling precision medicine, and providing versatile applications, it also poses risks like off-target effects, technical challenges, and concerns about long-term safety.",
+ "question": "What are the potential benefits and risk associated with gene editing technologies like CRISPRR-Cas9?"
+} \ No newline at end of file